Pharma Mar shares up 42% in 5 days
PharMar shares (PHM.ES) recorded a strong impulse of more than 30% thanks to promising clinical trials of Zepzelka, a lung cancer drug. The strong results boosted the future prospects for the Spanish pharmaceutical company, which saw several research firms raise their target price for the stock.
Optimism boosts Pharma Mar shares
Preliminary results from a Phase III trial of Pharma Mar’s new lung cancer drug Zepzelka. demonstrated significant improvements in disease slowing and patient survival. These strong results brought with them strong support in the stock market, since for a company the size of Pharma Mar, such achievements could lead to a significant increase in revenue if the trial finally turns into a commercial drug. In this scenario Pharma Mar plans to apply for registration in Europe in 2025and its partner Jazz Pharmaceuticals will do the same in the US.
The news prompted research firms such as RX Securities and Bankinter to raise their forecasts for Pharma Mar shares. In particular, RX Securities increased its target price for the pharmaceutical company’s shares by 23%, setting it at 80 euros per share. Bankinter, for its part, also updated its estimate, increasing the price from 56 to 80 euros per share and highlighting the growth potential of the drug. Despite this, the highest price target for Phama Mar shares was given by JB Capital, which, according to Bloomberg, raised it to 102 euros per share, compared to the previously set 57 euros.
According to Bloomberg analysts, nevertheless, Pharma Mar stock would be overvalued now. The analyst company’s experts set the average price of the pharmaceutical company’s securities at 58.95 euros, which is far from the high prices set by other analyst companies.
Against all odds, Pharma Mar shares have soared 62% this year.
Source: XTB Platform.
The content provided in the TRAINING section is intended for informational, educational purposes and to support the use of the platform only. The material presented, including analyses, prices, opinions or other content, does not constitute investment advice or information that recommends or suggests an investment strategy, nor does it fall within the scope of investment advice included in Law 6/2023. Services (Article 125.1 g). This video has not been prepared taking into account the needs of the client or individual financial situation.
XTB is not responsible for any loss or damage of any kind, including, but not limited to, any lost profits, which may arise directly or indirectly from the use of or reliance on the information contained in this video. XTB SA is not responsible for the actions or inactions of the client, especially for the acquisition or sale of financial instruments made on the basis of the information contained in this video.
Past performance is not necessarily an indication of future results and anyone who acts upon this information does so at their own risk.
Copyright © XTB SA. All rights reserved. It is prohibited to copy, modify or distribute this video without the express consent of XTB SA.